Praluent partners Sanofi and Regeneron have been battling for market share against Amgen’s Repatha in the PCSK9 class of cholesterol drugs, including by recently lowering their price. Now, the ...

It’s no secret that the two existing PCSK9 cardiovascular drugs on the market, Amgen’s Repatha and Regeneron and Sanofi’s Praluent, are suffering from painfully slow launches. And on top of that, they ...

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

Regeneron and Sanofi will cut the price of their cholesterol drug Praluent by 60 percent to $5,850 a year, matching an unprecedented move that rival Amgen made with its medicine Repatha, the drug ...

The judge's ruling allows 30 days for an appeal but encourages the parties to work out a settlement. The case involves competing, expensive drugs to control cholesterol. A federal judge stunned Sanofi ...

The PCSK9 drugs are stirring up a lot of attention, primarily around how to restrict access. But, no one is talking about how to best manage the patient's needs. The PCSK9 drugs continue to remain in ...

In 2015, the launch of two new potent drugs to lower LDL-cholesterol (LDL-c) , Repatha (Amgen) and Praluent (Sanofi/Regeneron), sent shivers down the spines of payers. These drugs, the first of a ...

(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the price of Repatha by 60 ...

A. Your doctor was correct that depression and suicidal thoughts do not appear in the official prescribing information for evolocumab (Repatha) or a similar drug, alirocumab (Praluent). Both are ...

With high prices of drugs becoming an object of regulatory actions by the Trump administration, one company has taken steps to lower the prices of a biologic for which it won approval a few years ago.